An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapy An allocation by random phase II/III trial of doxycyclinein comparison to standard therapy in newly- ...
A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox A randomized phase II/III trial of doxycyclinevs. standard supportive therapy in newly-diagnosed car ...
Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunction of the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specify Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plas ...
A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy A Trial of Doxycyclinevs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Pati ...
A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy A Randomized Phase II/III Trial of Doxycyclinevs. Standard Supportive Therapy in Newly-diagnosed Car ...
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) Amyloidosis Doxycyclineto Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open L ...